Pay in 4 interest-free payments of $7.48 Learn more
Ships within 48 hours · Estimated delivery Oct 18 - Oct 23
[PMID 41837981] DRUG INTERACTIONS NOTE: The drug interactions presented here are NOT all-inclusive
Scientific name Melanotan II (MT-II) Brand VaultLabs Product code 12 Format Lyophilized Storage 28 C UAE dispatch All seven emirates
The participants were divided into the following experimental groups or a placebo group: 1 mg of retatrutide (subcutaneously) 4 mg of retatrutide (subcutaneously), starting at an initial dose of 2 mg 4 mg of retatrutide (subcutaneously), starting at an initial dose of 4 mg 8 mg of retatrutide (subcutaneously), starting at an initial dose of 2 mg 8 mg of retatrutide (subcutaneously), starting at an initial dose of 4 mg 12 mg of retatrutide (subcutaneously), starting at an initial dose of 2 mg Here are the detailed results of the trial at 24 weeks and 48 weeks: Phase II clinical trial projects promising results of retatrutide in weight management
This includes watching for signs of fever, such as: Increased body temperature Chills or shivering Sweating more than usual Feeling unusually tired or weak Muscle aches By paying attention to these signs, you can catch any issues early and address them before they become serious
Eligible patients received a stable dose of tirzepatide for at least 3 months and had available data for body weight and glycated hemoglobin (HbA1c) both before and after treatment
